Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report issued on Friday. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial cut their price objective on Fresenius Medical Care from $24.00 to $22.00 and set a hold rating on the stock in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Hold and an average price target of $22.00.

Fresenius Medical Care Stock Down 0.8 %

FMS stock opened at $19.67 on Friday. The stock’s fifty day simple moving average is $19.33 and its two-hundred day simple moving average is $19.85. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $23.29. The stock has a market cap of $11.54 billion, a P/E ratio of 22.10, a P/E/G ratio of 1.03 and a beta of 0.90.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.28 billion. Analysts expect that Fresenius Medical Care will post 1.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in FMS. Wulff Hansen & CO. lifted its position in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares during the last quarter. Moran Wealth Management LLC purchased a new stake in Fresenius Medical Care during the 4th quarter worth about $3,247,000. Partnership Wealth Management LLC purchased a new stake in Fresenius Medical Care during the 4th quarter worth about $2,340,000. Triasima Portfolio Management inc. purchased a new stake in Fresenius Medical Care during the 1st quarter worth about $1,293,000. Finally, Corient Private Wealth LLC lifted its holdings in Fresenius Medical Care by 164.6% during the 4th quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock worth $1,378,000 after purchasing an additional 41,139 shares in the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.